- ►prsjournal.com AE Fung, PJ Rosenfeld, E Reichel - British Journal of Ophthalmology, 2006 - bjo.bmj.com Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given
for the treatment of neovascular and exudative ocular diseases since May 2005.
Since then, the use of intravitreal bevacizumab has spread worldwide, but ... Cited by 230 - Related articles - BL Direct - All 14 versions
WM Chan, TYY Lai, DTL Liu, DSC Lam - American Journal of Ophthalmology, 2007 - Elsevier At baseline, the mean logMAR BCVA was 0.48 (Snellen equivalent = 20/60). The
mean logMAR BCVA improved significantly to 0.25 (Snellen equivalent = 20/36) and
0.17 (Snellen equivalent = 20/30) at one and six months, respectively (both ... Cited by 31 - Related articles - All 12 versions
JB Jonas, T Libondi, AK Ihloff, B Harder, I … - Acta Ophthalmologica Scandinavica, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 26 - Related articles - BL Direct - All 3 versions
- ►duanessolution.com E Yoeruek, MS Spitzer, O Tatar, S Aisenbrey, … - Cornea, 2007 - journals.lww.com Methods: Cell cultures of corneal keratinocytes (CKs), corneal fibroblasts
(CFs), and corneal endothelial cells (CECs) were har- vested from human donor
eyes and exposed to various concentra- tions of bevacizumab (0.25–5.0 ... Cited by 26 - Related articles - BL Direct - All 4 versions
- ►iovs.org UU Inan, B Avci, T Kusbeci, B Kaderli, R Avci … - Investigative Ophthalmology & Visual Science, 2007 - ARVO METHODS. Twenty-four rabbits were divided into two groups, each with two
subgroups. The first group (groups 1 and 2) received 1.25 mg (0.05 mL)
intravitreal bevacizumab, and the second group (groups 3 and 4) received ... Cited by 26 - Related articles - BL Direct - All 3 versions
MS Spitzer, E Yoeruek, A Sierra, B … - Graefe's Archive for Clinical and Experimental …, 2007 - Springer Page 1. RETINAL DISORDERS Comparative antiproliferative and cytotoxic profile
of bevacizumab (Avastin), pegaptanib (Macugen) and ... Cited by 23 - Related articles - BL Direct - All 2 versions
RJ Epstein - Cancer and Metastasis Reviews, 2007 - Springer Abstract The vascular endothelial growth factor (VEGF) family of polypeptide
growth factors regulates a family of VEGF receptor (VEGFR) tyrosine kinases with
pleiotropic downstream effects. Angiogenesis is the best known of these ... Cited by 24 - Related articles - BL Direct - All 3 versions
- ►duanesolution.com A Iriyama, YN Chen, Y Tamaki, Y Yanagi - British Journal of Ophthalmology, 2007 - bjo.bmj.com Aim: Intravitreal injection of anti-vascular endothelial growth factor (VEGF)
antibody (bevacizumab, Avastin) has become one of the chief choices for the
treatment of macular oedema and neovascular age-related macular ... Cited by 16 - Related articles - BL Direct - All 6 versions
R Simo, C Hernandez - Diabetologia, 2008 - Springer Abstract Vascular endothelial growth factor (VEGF) plays a key role in the
development of both proliferative diabetic retinopathy (PDR) and diabetic
macular oedema (DMO). In recent years, anti-VEGF agents have emerged as new ... Cited by 13 - Related articles - All 3 versions
